Our Impact and Reach
Since our founding in 1987, ACTG investigators and sites across four continents have served as major resources for HIV and other infectious disease research, treatment, care, and education in their communities.
47k+
participants
65
sites
15
countries
3k+
trials
Our Trials Locations Worldwide
Botswana
Botswana
Brazil
Haiti
India
Kenya
Malawi
Malawi
Mexico
Mexico
Peru
Peru
South Africa
Thailand
Uganda
USA
USA
Brigham and Women’s Hospital Therapeutics (BWH TCRS) CRS
Massachusetts General Hospital (MGH) CRS
Case Clinical Research Site CRS
Columbia Physicians & Surgeons (P&S) CRS
De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC)
University of California, San Francisco HIV/AIDS CRS
University of Washington Positive Research CRS
Houston AIDS Research Team (HART) CRS
UCSD Antiviral Research Center CRS
University of Colorado Hospital CRS
Harbor University of California Los Angeles Center CRS
University of California, Los Angeles CARE Center CRS
University of Rochester Adult HIV Therapeutic Strategies Network CRS
Vanderbilt Therapeutics (VT) CRS
Washington University Therapeutics (WT) CRS
Vietnam
Vietnam
Zimbabwe
Zimbabwe
Enrolling Study Highlight
A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Disease Study Description: A5418 (STOMP) study is designed to evaluate the safety and effectiveness of tecovirimat (TPOXX) in treating human monkeypox virus (HMPXV) disease. Participants, who must have a laboratory-confirmed or presumptive monkeypox infection lasting less than 14 days and present with at least one active skin or mouth lesion, or proctitis, will be randomly assigned in a 2:1 ratio to receive either tecovirimat or a placebo for 14 days. Those at higher risk for severe disease, due to age or medical history, will be assigned to receive open-label tecovirimat. The study will track participants over a two-month period through a combination of in-person visits, specimen collection, virtual assessments, and self-reports, including photographs of symptoms. Tecovirimat, an FDA-approved drug for treating smallpox in adults and children, is being tested in this study as an investigational treatment for infections caused by pox viruses.
Words Matter!
The NIAID HIV Language Guide is a means to advance the use of person-first, inclusive, and respectful language. The continued use of language known to be offensive and stigmatizing is insensitive and disrespectful. NIAID and ACTG are making every effort to eliminate such terminology and advance the use of person-first, inclusive, and respectful language. This updated language guide is an important step toward that end. With it, NIAID is also embarking on a campaign to educate and strongly advocate for person-first, non-stigmatizing language in all our communications, including but not limited to grant applications, contracts, publications, presentations, abstracts, and press materials. We will also encourage the use of person-first language at all meetings, workshops, and conferences.
Voices for the Community
Sign up to receive the latest updates from ACTG
